Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
对利拉夫格拉替尼的复发性耐药突变可指导 FGFR2 驱动肿瘤的治疗顺序。
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-4390
Facchinetti Francesco, Hollebecque Antoine, Barbé Rémy, Jang Dong Man, Alonso-De-Castro Beatriz, Brayé Floriane, Bigot Ludovic, Nobre Catline, Da Silva Alice, Méteau Mélissandre, Delavigne Mathis, Soares Miguel, Italiano Antoine, Rodriguez Julieta, Mosele Fernanda, Beshiri Kristi, Ducreux Michel, Boilève Alice, Nikolaev Sergey, Alonso-Garcia Inmaculada, Vasseur Damien, Smolenschi Cristina, Bourien Héloise, Cotteret Sophie, Samaniego Juliette, Bernard Elsa, Nicotra Claudio, Ngo-Camus Maud, Nakazawa Seshiru, Tselikas Lambros, Badoual Cécile, André Fabrice, Eck Michael J, Olaussen Ken A, Loriot Yohann, Friboulet Luc
